{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:45:52Z","timestamp":1793987152719,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.parkreldis.2013.11.005","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T01:45:54Z","timestamp":1384393554000},"page":"212-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy"],"prefix":"10.1016","volume":"20","author":[{"given":"Ayaka","family":"Numao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2013.11.005_bib1","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/WNL.0b013e3182752eef","article-title":"Insulin-like growth factors in the brain and their potential clinical implications","volume":"79","author":"Benarroch","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF03346653","article-title":"Growth hormone\/insulin-like growth factor I axis in neurodegenerative diseases","volume":"33","author":"Gasperi","year":"2010","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/jnnp.2009.175752","article-title":"Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease","volume":"81","author":"Godau","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/archneurol.2011.129","article-title":"Serum insulin like growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease","volume":"68","author":"Godau","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jocn.2009.08.013","article-title":"Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease","volume":"17","author":"Mashayekhi","year":"2010","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib6","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/mds.23320","article-title":"Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system","volume":"25","author":"Pellecchia","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2265.2005.02237.x","article-title":"Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia","volume":"62","author":"Pellecchia","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib8","first-page":"1724","article-title":"Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naive Parkinson's disease","volume":"260","author":"Picillo","year":"2013","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib13","series-title":"Recent development in Parkinson's disease","first-page":"153","article-title":"Unified Parkinson's disease rating scale","author":"Fahn","year":"1987"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/1531-8257(200003)15:2<276::AID-MDS1010>3.0.CO;2-Q","article-title":"Application of the unified Parkinson's disease rating scale in progressive supranuclear palsy: factor analysis of the motor scale","volume":"15","author":"Cubo","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib15","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/mds.20255","article-title":"Development and validation of the unified multiple system atrophy rating scale (UMSARS)","volume":"19","author":"Wenning","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib16","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib17","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(96)10168-9","article-title":"Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine","volume":"349","author":"Kimber","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib18","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/brain\/123.7.1422","article-title":"Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy","volume":"123","author":"Kimber","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2013.11.005_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-012-6648-6","article-title":"Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naive Parkinson's disease","author":"Pellecchia","year":"2013","journal-title":"Eur J Neurol"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802013003970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802013003970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T15:54:10Z","timestamp":1539186850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802013003970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1353802013003970"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2013.11.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2013.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}